Nuvalent, Inc., was incorporated under the laws of the State of Delaware on January 25, 2017. The company is a clinical-stage biopharmaceutical company focused on creating precision targeted therapies for cancer patients. The company leverages the team's deep expertise in chemistry and structure-based drug design to develop innovative small molecules designed to overcome the limitations of existing therapies on clinically proven kinase targets. Limitations faced by currently available kinase inhibitors may include (i) kinase resistance, or the emergence of new mutations in the kinase target that enable resistance to existing therapies, (ii) kinase selectivity, or existing therapies that may inhibit structurally similar kinase targets and cause off-target adverse events, and (iii) limited brain penetration, or the ability of the therapy to treat diseases that have spread or metastasized to the brain.